65
Participants
Start Date
March 25, 2015
Primary Completion Date
October 23, 2019
Study Completion Date
December 31, 2020
Durvalumab
10 mg/kg, mg intravenous (IV), every two weeks, or 1500 mg, IV, every four weeks.
Tremelimumab
75 mg IV, every 4 weeks for 16 weeks
Sterostatic body radiation therapy (SBRT)
8 Gray (Gy) x 1; 5Gy x 5
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda
National Cancer Institute (NCI)
NIH